Protecting against pneumococcal disease: critical interactions between probiotics and the airway microbiome
- PMID: 22685396
- PMCID: PMC3369940
- DOI: 10.1371/journal.ppat.1002652
Protecting against pneumococcal disease: critical interactions between probiotics and the airway microbiome
Conflict of interest statement
I have read the journal's policy and have the following conflicts: MT is chairman of the Asia Pacific Immunoglobulins in Immunology Expert Group (APIIEG), which is supported by CSL Ltd and is a member of the Nestle Nutrition Institute Medical Advisory Board, Australia/New Zealand. All other authors declare they have no conflicts of interest.
Figures

References
-
- O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893–902. - PubMed
-
- Said MA, O'Brien KL, Nuorti JP, Singleton R, Whitney CG, et al. The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations. Vaccine. 2011;29:5355–5362. - PubMed
-
- Jacups SP, Cheng A. The epidemiology of community acquired bacteremic pneumonia, due to Streptococcus pneumoniae, in the Top End of the Northern Territory, Australia–over 22 years. Vaccine. 2011;29:5386–5392. - PubMed
-
- Malley R. Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development. J Mol Med (Berl) 2010;88:135–142. - PubMed
-
- Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, et al. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Clin Ther. 2008;30:341–357. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical